Physician profile
Tyler Case Nesmith
NPI 1326401654
$1,444.84
in general payments reported to CMS, 2019-2025
22 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $168 · 2021: $167 · 2022: $375 · 2023: $213 · 2024: $342 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.46 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.49 | 2022-2025 | Lifevest |
| Abbott Laboratories | $172.98 | 2020-2023 | Pressurewire |
| Abiomed | $155.44 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $135.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $130.32 | 2022-2024 | Farxiga |
| Esperion Therapeutics, INC. | $129.30 | 2021 | |
| Medtronic, INC. | $93.22 | 2022 | |
| Amgen INC. | $63.01 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $55.19 | 2022-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.27 | 2024 | Jardiance |
| Pfizer INC. | $30.95 | 2021-2022 | |
| Teleflex LLC | $24.67 | 2025 | Guideliner |
| Philips North America LLC | $23.31 | 2023 | |
| Daiichi Sankyo INC. | $21.81 | 2024 | Injectafer |
| Lantheus Medical Imaging, INC. | $21.60 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $20.12 | 2024 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Actelion Pharmaceuticals US, INC. | $17.71 | 2022 | |
| Scpharmaceuticals INC. | $16.76 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.75 | 2024 | Xarelto |
| Boston Scientific Corporation | $15.85 | 2022 | |
| Edwards Lifesciences Corporation | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Nesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.